Delcath Systems Inc (DCTH)

[Fisher Man]

No sweat, I understand...it's not easy to listen to drab mundane stuff not in one's wheelhouse......bottom line is that there are 2 treatments at the moment better than others for liver mets from ocular melanoma, delcath and gp100. Delcath has a good product, but, I agree with many here that the business end could have been handled better, and personally I am not interested in investing, mainly for other reasons, even though it is a treatment I would choose, or even yearn for if I were in the spot.

What is disappointing to me as an eye surgeon, is that one of my best friends has the disease, and is nearly disease free after delcath, beating historical odds, but the company from the outside seems to be poorly run. It seems that Delcath targeted metatstatic uveal melanoma, knowing that approval would open other avenues, which is reasonable. I don't understand why the phase III trial did not have a crossover arm to begin with.....this hurt recruitment, and forced my friend to England to pay out of pocket....hence, low US phase 3 recruitment, spending more money hoping for improved numbers...but if your treatment is reportedly so much better, who wants to be randomized to the other arm of the trial, especially if there is no choice to crossover if your randomized assignment doesn't work? No crossover was not a smart decision...